APA (7th ed.) Citation

C, L., S, S., HA, L., M, B., A, E., M, K., . . . T, C. (2025). A20 (TNFAIP3) Distinguishes Attack From Remission in Pediatric Patients With Monophasic MOGAD. Neurology(R) neuroimmunology & neuroinflammation, 12(5), e200452. https://doi.org/10.1212/NXI.0000000000200452

Chicago Style (17th ed.) Citation

C, Lechner, et al. "A20 (TNFAIP3) Distinguishes Attack From Remission in Pediatric Patients With Monophasic MOGAD." Neurology(R) Neuroimmunology & Neuroinflammation 12, no. 5 (2025): e200452. https://doi.org/10.1212/NXI.0000000000200452.

MLA (9th ed.) Citation

C, Lechner, et al. "A20 (TNFAIP3) Distinguishes Attack From Remission in Pediatric Patients With Monophasic MOGAD." Neurology(R) Neuroimmunology & Neuroinflammation, vol. 12, no. 5, 2025, p. e200452, https://doi.org/10.1212/NXI.0000000000200452.